(FM) Oncología

2024

1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future Oncology, Vol. 20, Núm. 13, pp. 799-809

3. Access to melanoma drugs in Spain: a cross-sectional survey

   Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

4. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

   Clinical and Translational Oncology

5. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

   Molecular Cancer, Vol. 23, Núm. 1

6. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

   International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

7. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

   Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

8. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

9. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

10. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

11. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

    European Journal of Cancer, Vol. 202

12. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

13. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer

    Seminars in Oncology Nursing, Vol. 40, Núm. 1

14. Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

    Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347

15. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

16. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

17. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

    Clinical Genitourinary Cancer, Vol. 22, Núm. 5

18. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

19. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

20. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138